(:UROV)

Mar 07, 2022 11:56 am ET
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies.
Dec 20, 2021 12:11 pm ET
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA®
Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Advances in Therapy has published patient-perception data supporting clinical meaningfulness of overactive bladder (OAB) symptom reduction for its FDA-approved OAB therapy, GEMTESA® (vibegron), compared to placebo. The article entitled, “Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR” is available
Nov 08, 2021 08:00 am ET
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved overactive bladder (OAB) therapy, GEMTESA® (vibegron) in the U.S. The peer-reviewed publication is currently available
Feb 12, 2021 04:05 pm ET
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended December 31, 2020.
Feb 11, 2021 08:00 am ET
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI).
Feb 04, 2021 04:08 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 30, 2021 06:06 pm ET
Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - CPAH, UROV, ANH, CGIX, CBLI, NEOS
NEW YORK, Jan. 30, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:
Jan 25, 2021 01:20 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jan 24, 2021 10:10 am ET
Jan 20, 2021 11:17 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates COHR, CBMG, WTRE, NAV, UROV; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 16, 2021 02:54 pm ET
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jan 15, 2021 08:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 12, 2021 09:54 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates FFG, NHLD, HCAP, NAV, UROV; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 10, 2021 09:30 am ET
Jan 08, 2021 08:30 pm ET
MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Jan 05, 2021 10:31 am ET
ALERT: Halper Sadeh LLP Investigates WTRE, CIT, ALSK, NAV, UROV; Shareholders Are Encouraged to Contact the Firm
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 30, 2020 10:16 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – UROV, EIGI, SNCA, CLCT
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Dec 29, 2020 07:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of UROV, SNSS, TCF, and PS Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Urovant Sciences Ltd. (NASDAQ GS: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitovant Biopharma...
Dec 28, 2020 07:30 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 23, 2020 04:05 pm ET
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg GEMTESA® (vibegron), a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. This approval marks the first new oral branded OAB medication approved by the FDA since 2012, and it is the first product approval for Urovant Sciences.
Dec 22, 2020 08:00 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – WDR, WORK, INFO, UROV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Waddell & Reed Financial, Inc. (NYSE: WDR) concerning potential violations of the federal securities laws and/or breaches of fiduciary...
Dec 19, 2020 03:28 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - CKH, HBAN, PS, UROV, XLNX
NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 17, 2020 02:55 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of WDR, CLCT, NAV, and UROV Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Waddell & Reed Financial, Inc. (NYSE: WDR) regarding possible breaches of fiduciary duties and other violations of law related to Waddell’s agreement to be acquired by affiliates of...
Dec 16, 2020 10:43 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – EIGI, XLNX, UROV, HDS
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Endurance International Group Holdings, Inc. (NASDAQ: EIGI) concerning potential violations of the federal securities laws and/or...
Dec 15, 2020 05:10 pm ET
MERGER ALERT - UROV, CGRO, and CKH: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of These Companies
NEW YORK, NY / ACCESSWIRE / December 15, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Dec 12, 2020 09:10 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm - EIGI, CKH, UROV, PNM, INFO
NEW YORK, Dec. 12, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Dec 09, 2020 12:56 pm ET
Dec 08, 2020 09:53 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – CKH, EIGI, HDS, UROV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following mergers: SEACOR Holdings Inc. (NYSE: CKH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
Dec 07, 2020 04:10 pm ET
MERGER ALERT - UROV and GV: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / December 07, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.Urovant Sciences Ltd. (NASDAQ:UROV)
Dec 04, 2020 10:46 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - WORK, WDR, BBIO, UROV, HDS
NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Dec 03, 2020 01:13 pm ET
UROVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant Sciences (NasdaqGS: UROV) to Sumitovant Biopharma. Under the terms of the proposed transaction, shareholders of Urovant will receive only $16.25 in cash for each share of Urovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 01, 2020 06:59 pm ET
Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – NAV, UROV, HDS, AKER
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Navistar International Corporation (NYSE: NAV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Dec 01, 2020 11:09 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, UROV, AKER, and EMIS Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Navistar International Corporation (NYSE: NAV) regarding possible breaches of fiduciary duties and other violations of law related to Navistar’s agreement to be acquired by TRATON SE....
Nov 30, 2020 07:45 pm ET
Nov 30, 2020 04:00 pm ET
MERGER ALERT – HDS, and UROV: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / November 30, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Nov 25, 2020 10:41 pm ET
Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – UROV, HDS, AKER, GV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...
Nov 25, 2020 07:01 am ET
Nov 24, 2020 04:05 pm ET
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).
Nov 24, 2020 11:49 am ET
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:
Nov 20, 2020 11:04 am ET
Moore Kuehn Encourages DNKN, HDS, CEIX and UROV Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek...
Nov 19, 2020 06:11 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of HDS, UROV, AKER, and TGC Mergers
Rigrodsky & Long, P.A. announces that it is investigating: HD Supply Holdings, Inc. (NASDAQ GS: HDS) regarding possible breaches of fiduciary duties and other violations of law related to HD Supply’s agreement to be acquired by The Home Depot,...
Nov 19, 2020 08:00 am ET
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks. The data demonstrate that vibegron improved quality of life (QoL) and incontinence efficacy endpoints with good long term tolerability in adult patients with overactive bladder (OAB) and symptoms of urge urinary incontinence (UUI), urgency and urinary frequency.
Nov 18, 2020 03:15 pm ET
RM LAW Announces Investigation of Urovant Sciences Ltd.
BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ --  RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant's agreement to be acquired by Sumitovant Biopharma Ltd.
Nov 18, 2020 08:00 am ET
Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – HDS, UROV, AKER, NAV
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: HD Supply Holdings, Inc. (NASDAQ: HDS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...
Nov 17, 2020 08:31 pm ET
UROVANT SCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Urovant Sciences - UROV
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant Sciences (NasdaqGS: UROV) to Sumitovant Biopharma. Under the terms of the proposed transaction, shareholders of Urovant will receive only $16.25 in cash for each share of Urovant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Nov 13, 2020 07:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV
NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Urovant Sciences Ltd. ("Urovant" or the "Company") (UROV) relating to its proposed acquisition by Sumitovant Biopharma Ltd. Under the terms of the agreement, Urovant shareholders are expected to receive approximately $16.25 in cash per share.
Nov 13, 2020 06:17 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Urovant Sciences Ltd. Buyout
Rigrodsky & Long, P.A. announces that it is investigating Urovant Sciences Ltd. (“Urovant”) (NASDAQ GS: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitovant...
Nov 13, 2020 03:06 pm ET
UROVANT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of UROV and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Urovant Sciences Ltd. (NASDAQ: UROV) breached their fiduciary duties or violated the federal...
Nov 13, 2020 02:04 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV" or the "Company") (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. ("Sumitovant"), UROV's majority shareholder that currently owns 72% of the Company's outstanding common shares. Under the terms of the acquisition agreement, the Company's shareholders will receive only $16.25 in cash for each share of UROV common stock that they own
Nov 13, 2020 09:47 am ET
Urovant Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Urovant Sciences Ltd. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – UROV
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Urovant Sciences Ltd. (NASDAQ: UROV) to Sumitovant Biopharma Ltd. for $16.25 per share is fair to Urovant shareholders. On behalf of Urovant shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Nov 12, 2020 05:18 pm ET
Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
Urovant Sciences (Nasdaq: UROV) announced today that it has entered into a definitive agreement in which Sumitovant Biopharma will acquire Urovant Sciences for $16.25 per share or approximately $584 million in total equity value on a fully diluted basis in an all-cash merger. The price represents a 96% premium over Urovant’s closing share price of $8.28 on November 12, 2020 and a premium of 92% to Urovant’s 30-day volume weighted average share price on November 12, 2020. Sumitovant is currently Urovant’s largest shareholder with approximately 72% equity ownership of the company.
Nov 12, 2020 04:00 pm ET
Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant
NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a definitive merger agreement for Sumitovant to acquire the outstanding shares of Urovant common stock not already owned by Sumitovant at a price of $16.25 per share in cash. Sumitovant currently owns 72% of the outstanding shares of Urovant common stock.
Nov 10, 2020 08:00 am ET
Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, November 17, 2020, at the Jefferies Virtual London Healthcare Conference.
Nov 02, 2020 04:05 pm ET
Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020.
Oct 27, 2020 08:00 am ET
Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020.
Oct 07, 2020 08:00 am ET
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment upon receiving U.S. Food and Drug Administration (FDA) approval for the drug. In March 2020, the FDA accepted the New Drug Application (NDA) for vibegron in overactive bladder (OAB) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020.
Sep 08, 2020 08:00 am ET
Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually.
Aug 13, 2020 04:05 pm ET
Urovant Sciences Reports Fiscal First Quarter 2020 Results
Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020.
Aug 06, 2020 08:00 am ET
Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020.
Jun 18, 2020 04:05 pm ET
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.
Jun 18, 2020 08:00 am ET
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd.
Jun 11, 2020 08:00 am ET
Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results
Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020.
Jun 02, 2020 08:00 am ET
Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access
Urovant Sciences (Nasdaq: UROV) today announced the appointment of Walt Johnston as Senior Vice President of Commercial and Kenton Stewart as Senior Vice President of Market Access, both reporting to Urovant CEO James Robinson.
May 27, 2020 08:00 am ET
Urovant Sciences Appoints James Hindman to Board of Directors
Urovant Sciences (Nasdaq: UROV) today announced the appointment of Jim Hindman to the company’s Board of Directors. A veteran of the pharmaceutical, biologics and medical device industries, Mr. Hindman brings more than 30 years of financial and strategic experience to his new role.
May 26, 2020 08:00 am ET
Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
Urovant Sciences (Nasdaq: UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually.
May 14, 2020 08:00 am ET
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study (NCT03583372) and data by age groups from the 12-week placebo-controlled EMPOWUR study (
Mar 23, 2020 04:05 pm ET
Urovant Sciences Appoints James Robinson as President and Chief Executive Officer
Urovant Sciences (Nasdaq: UROV) today announced the appointment of accomplished industry veteran Jim Robinson to the position of President and Chief Executive Officer. Mr. Robinson will continue his service as a member of the Urovant Board of Directors. Mr. Robinson is succeeding Urovant’s founding CEO Keith Katkin, who will transition to the role of advisor to the Urovant Board for the next five years.
Mar 05, 2020 08:00 am ET
Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Urovant Sciences (Nasdaq: UROV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for once-daily 75 mg vibegron for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Mar 02, 2020 08:00 am ET
Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology
Urovant Sciences (Nasdaq: UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial. The peer-reviewed publication is currently available online and the print article is scheduled to be published in the
Feb 25, 2020 08:00 am ET
Urovant Sciences to Present at Cowen and Company’s 40th Annual Health Care Conference
Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company’s 40th Annual Health Care Conference in Boston.
Feb 13, 2020 04:15 pm ET
Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019.
Feb 06, 2020 08:00 am ET
Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020.
Feb 04, 2020 08:00 am ET
Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder
Urovant Sciences (Nasdaq: UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1 trials. The first trial was conducted with instillation therapy and the second trial with direct injections into the bladder wall under local anesthesia. The peer-reviewed publication was published online in Neurology and Urodynamics. URO-902, a naked DNA plasmid-based gene therapy administered via injection directly into the bladder, is currently being evaluated
Jan 17, 2020 08:00 am ET
Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell
Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin and other Urovant executives will ring the opening bell of the Nasdaq Stock Market on Tuesday, January 21, 2020, at 9:30 a.m. Eastern.
Jan 08, 2020 08:00 am ET
Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Urovant Sciences (Nasdaq: UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 4:30 p.m. Pacific / 7:30 p.m. Eastern on Wednesday, January 15, 2020, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
Dec 30, 2019 04:15 pm ET
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of once-daily 75mg vibegron for the treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Dec 30, 2019 08:05 am ET
Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo Dainippon Pharma
Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that it has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company. Urovant plans to use proceeds from this facility to repay existing debt, fund ongoing development projects, fund the initial commercial launch of vibegron if approved by the FDA, and for general corporate purposes.
Dec 30, 2019 08:00 am ET
Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance
Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical company, have completed their transaction that creates a significant, multinational Sumitomo Dainippon Pharma-Roivant Alliance (“Alliance”), including the transfer of Roivant’s ownership interests in Urovant, as well as four additional biopharmaceutical “Vant” companies, to the Alliance. The Alliance will operate as Sumitovant Biopharma Ltd.
Dec 23, 2019 08:00 am ET
Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
Urovant Sciences (Nasdaq: UROV), announced today that the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) suffering with urge urinary incontinence (UUI).
Nov 05, 2019 04:05 pm ET
Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 second fiscal quarter ended September 30, 2019.
Oct 31, 2019 09:29 am ET
Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma
Urovant Sciences (Nasdaq: UROV) today announced that its majority shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a definitive agreement for the creation of a broad Sumitomo Dainippon-Roivant Strategic Alliance that will include the transfer from Roivant Sciences to Sumitomo Dainippon Pharma of all of Roivant’s ownership interests in Urovant Sciences.
Oct 29, 2019 08:00 am ET
Urovant Sciences to Report 2019 Second Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 second fiscal quarter financial results after the close of U.S. financial markets on Tuesday, November 5, 2019.
Oct 21, 2019 08:00 am ET
Urovant Sciences Initiates Part 2 of Phase 3 COURAGE Study of Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety and efficacy of vibegron for the treatment of symptoms of overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH).
Sep 24, 2019 09:00 am ET
Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
As previously reported, once-daily vibegron met both co-primary endpoints in the 12-week Phase 3 EMPOWUR study, achieving statistical significance over placebo on both reduction in daily urge urinary incontinence (UUI) episodes (p
Sep 06, 2019 09:00 am ET
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memorandum of understanding for the creation of a significant multi-national Sumitomo Dainippon-Roivant Alliance (“Alliance”) that will include Roivant’s ownership interests in Urovant Sciences and four additional biopharmaceutical “Vant” companies. Roivant will collaborate with Sumitomo Dainippon Pharma, with continued involvement of Roivant’s senior leaders, to ensure t
Aug 13, 2019 04:05 pm ET
Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019.
Aug 06, 2019 08:00 am ET
Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter financial results after the close of U.S. financial markets on Tuesday, August 13, 2019.
Jun 13, 2019 04:05 pm ET
Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019.
Jun 06, 2019 08:00 am ET
Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2019 after the close of U.S. financial markets on Thursday, June 13, 2019.
Jun 03, 2019 08:00 am ET
Urovant Sciences to Present at Annual Roivant Pipeline Day
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin will present at the annual Roivant Pipeline Day on June 6, 2019 at 1:50 p.m. ET.
May 30, 2019 08:00 am ET
Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 11:30 a.m. ET.
May 06, 2019 08:00 am ET
Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced Dr. David Staskin presented positive, Phase 3 pivotal data demonstrating safety and efficacy of vibegron during a plenary session at the 2019 American Urological Association Annual Meeting (AUA) in Chicago yesterday afternoon. Vibegron is an investigational novel, once-daily oral beta-3 adrenergic agonist being evaluated as a treatment for adults with sym
Apr 29, 2019 08:00 am ET
Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced two vibegron abstracts were accepted for plenary and podium presentations, respectively, at the 2019 American Urological Association Annual Meeting in Chicago May 3-6, 2019.
Mar 27, 2019 08:00 am ET
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological treatment for benign prostatic hyperplasia (BPH). Vibegron is an investigational beta-3 agonist that has previously been evaluated in Phase 2b and Phase 3 studies in patients with
Mar 19, 2019 08:00 am ET
Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced positive topline results from EMPOWUR, an international double-blind, placebo-controlled, multicenter Phase 3 clinical trial evaluating the efficacy and safety of vibegron 75mg in adults with symptoms of overactive bladder. Vibegron is an investigational once-daily oral beta-three adrenergic agonist.
Mar 18, 2019 04:05 pm ET
Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivotal phase 3 study on Tuesday, March 19, 2019 at 8:30 a.m. ET. A question and answer session will follow management’s remarks.
Mar 07, 2019 08:00 am ET
Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 at 8:40 a.m. ET.
Mar 06, 2019 08:00 am ET
Urovant Sciences Appoints James Robinson to its Board of Directors
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson, President and Chief Operating Officer of Alkermes, will join its Board of Directors.
Feb 22, 2019 05:20 pm ET
Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $100 million. Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes.
Feb 13, 2019 04:05 pm ET
Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended December 31, 2018.
Feb 06, 2019 08:00 am ET
Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter financial results after the close of U.S. financial markets on Wednesday, February 13, 2019.
Jan 15, 2019 08:00 am ET
Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019. The event will feature presentations by clinical experts in the field of urology, Dr. Roger R. Dmochowski, Vanderbilt University, and Dr. Steven Kaplan, Icahn School of Medicine at Mount Sinai.
Jan 03, 2019 08:00 am ET
Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018.
Jan 02, 2019 07:00 am ET
Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK and BASEL, Switzerland, Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of the business as well as new data updates from private companies in the Roivant family at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Dec 19, 2018 08:00 am ET
Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced chief executive officer Keith A. Katkin is scheduled to present a corporate overview at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:00 a.m. PT in San Francisco.
Nov 19, 2018 08:00 am ET
Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to participate in the Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 4:30 p.m. ET in New York City.
Nov 12, 2018 04:05 pm ET
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.
Nov 08, 2018 08:00 am ET
Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it completed enrollment in its international Phase 3 clinical trial, EMPOWUR, evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder. Vibegron is an investigational oral beta-3 adrenergic agonist.
Nov 05, 2018 08:00 am ET
Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results
Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it will report 2018 second fiscal quarter financial results after the close of U.S. financial markets on Monday, November 12, 2018.
Nov 01, 2018 08:00 am ET
Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced the publication of positive results from the international Phase 2b study of vibegron, an investigational oral beta-3 adrenergic agonist being studied for adults with symptoms of overactive bladder (OAB).
Sep 26, 2018 11:00 pm ET
Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
BASEL, Switzerland and IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced the pricing of its initial public offering of 10,000,000 common shares at a price to the public of $14.00 per share, for total gross proceeds of $140 million, before deducting underwriting discounts and commissions and other offering expenses payable by Urovant. In addition, Urovant has granted the underwriters a 30-day option to purchase up to 1,500,000 additional common

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.